Charles River Laboratories strategy focus, S&P 500 health stock in contract research
28.06.2026 - 14:34:49 | ad-hoc-news.de
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-28, 14:34.
Charles River Laboratories (US1591881009) is listed on the New York Stock Exchange under the ticker CRL and belongs to the US health sector, with a focus on outsourced research and laboratory services for pharmaceutical and biotech customers. The stock is part of the S&P 500 index, which anchors it in the broader US large-cap universe for international investors.
How Charles River earns its fees
Charles River Laboratories International Inc. has built its business around preclinical and clinical contract research services, enabling pharmaceutical and biotech companies to outsource essential development steps. The group offers laboratory-based services including safety assessment, discovery support and biologics testing, which together form a diversified revenue base across multiple therapy areas.
Within the global health-sector peer group, Charles River competes with specialist contract research organizations such as Labcorp and IQVIA, but maintains a strong niche in early-stage research and animal models for drug development. This positioning allows it to participate in long-term growth trends in biopharma R&D spending without bearing the full binary risk of individual drug approvals.
Operational setup and long-term strategy
The company’s operational strategy centers on being a full-service partner along the preclinical to early clinical development chain, with facilities in North America, Europe and Asia supporting global clients. Over time Charles River has expanded from its core animal research and safety testing into broader discovery and biologics capabilities, often via targeted acquisitions aimed at filling specific technological or geographic gaps.
In the US health sector, Charles River’s contract research model is designed to benefit from structural outsourcing trends, as large pharmaceutical groups and emerging biotechs seek flexible capacity and specialized expertise. By pooling projects across clients, the company can achieve scale efficiencies in laboratory operations, data handling and regulatory compliance, which is a central pillar of its long-term margin potential.
Background and data on the Charles River Laboratories shares
Further articles and key figures on Charles River Laboratories and its S&P 500-listed shares are available via the topic page and the company’s investor relations site.
The business behind the stock
Charles River Laboratories generates its revenue from a portfolio of contract research and laboratory services that cover critical stages in drug and medical device development. The company works under long-term framework agreements and project-based contracts with pharmaceutical majors, biotech firms and academic institutions, providing study design, execution, data analysis and regulatory documentation in a standardized and scalable format.
A key component of the business model is the ability to handle complex regulatory requirements, including Good Laboratory Practice standards and interaction with agencies such as the FDA, across multiple jurisdictions. This regulatory competence is monetized through repeat business and a reputation for reliability, which helps sustain client relationships and supports the stock’s role as a long-term exposure to global health-sector innovation.
Where the stock trades today
The Charles River Laboratories shares (US1591881009) trade on the New York Stock Exchange under the ticker symbol CRL, with the stock part of the S&P 500 health care segment. Current intraday price and market capitalization data are available via US exchange portals and broker platforms that track NYSE-listed securities.
Charles River Laboratories key data
- Company: Charles River Laboratories International Inc.
- ISIN: US1591881009
- WKN: 885256
- Ticker: CRL
- Trading venue: NYSE
- Price (as of 2026-06-28, 14:34): not live-verifiable in this dispatch
- Market cap: not specified in this dispatch
- Sector / industry: Health care - contract research and laboratory services
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not contain investment advice, tax advice or a recommendation to buy or sell securities. Data points are based on sources deemed reliable at the time of review but may change without notice; investors should consult exchange portals, broker data and official company publications for the latest figures.
